We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.
- Authors
Gómez‐Almaguer, David; Tarín‐Arzaga, Luz; Moreno‐Jaime, Brizio; Jaime‐Pérez, José Carlos; Ceballos‐López, Adrián Alejandro; Ruiz‐Argüelles, Guillermo J.; Ruiz‐Delgado, Guillermo J.; Cantú‐Rodríguez, Olga Graciela; Gutiérrez‐Aguirre, Cesar Homero; Sánchez‐Cárdenas, Mónica
- Abstract
Corticosteroids as initial therapy for primary immune thrombocytopenia achieve a low rate of sustained remission. Methods We prospectively evaluated the efficacy, safety, and response duration of low-dose rituximab plus high-dose dexamethasone as frontline therapy in newly diagnosed primary immune thrombocytopenia patients. One cycle of dexamethasone, 40 mg/d/intravenously for four consecutive days, plus weekly intravenous rituximab, 100 mg for four doses, was delivered. Results Twenty-one consecutive adults were enrolled. The overall response at day +28 was 90.5%. Complete sustained response at 6 months and relapse rate were 76.2% and 15.8%, respectively, compared with 30% and 62.5% for a historical group who had received standard treatment with prednisone ( P = 0.005 and P = 0.004). There was a 9.5% incidence of adverse effects. Conclusions The combination of low-dose rituximab and high-dose dexamethasone as frontline therapy for adults with primary immune thrombocytopenia was effective and had a high overall response rate and a low incidence of relapse.
- Subjects
ADRENOCORTICAL hormones; BLOOD platelet disorders; THROMBOCYTOPENIA; RITUXIMAB; DEXAMETHASONE
- Publication
European Journal of Haematology, 2013, Vol 90, Issue 6, p494
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.12102